NewAmsterdam Pharma (NAMS) Equity Ratio (2021 - 2026)

NewAmsterdam Pharma has disclosed Equity Ratio across 6 years of filings, most recently posting 0.91 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.91, down 4.41% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.91 (down 4.41% YoY), and the FY2025 annual result was 0.89, up 1.4% from the prior year.
• Equity Ratio came in at 0.91 for Q1 2026 at NewAmsterdam Pharma, up from 0.89 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.96 in Q2 2025 to a low of 0.73 in Q2 2023.
• The 5-year median for Equity Ratio is 0.88 (2024), against an average of 0.88.
• Across the five-year window, Equity Ratio fell 8.84% in 2023 and gained 19.18% in 2024, its largest moves.
• NewAmsterdam Pharma's Equity Ratio stood at 0.91 in 2022, then fell by 8.84% to 0.83 in 2023, then advanced by 5.44% to 0.88 in 2024, then rose by 1.4% to 0.89 in 2025, then advanced by 2.2% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.89 (Q4 2025), and 0.93 (Q3 2025), per Business Quant data.